“I have never seen weight loss at this level.”
In this post you’ll learn when retatrutide will realistically be available, what has to happen first, who can get it today, and what to do while you wait. About 5 minutes.
“Coming Soon” Has Been Coming Soon for Two Years
Retatrutide went viral in 2023. Since then, every few months someone online says it’s about to launch.
Meanwhile, websites sell vials labeled “retatrutide” right now. No prescription. Ships tomorrow.
Neither the countdown posts nor the sellers mention the boring part: the real timeline is public. It’s just less exciting than a rumor.
Action item: If a website sells you “retatrutide” today, close the tab. Lilly says the drug is only available in its trials and a narrow early-access program.
Where Retatrutide Stands Right Now (October 2026)
The big trials are in, and they’re strong:
- TRIUMPH-1 (May 2026): 28.3% average weight loss at 80 weeks on the 12 mg dose, in 2,339 adults without diabetes.
- TRIUMPH-2 (July 2026): up to 20.8% weight loss at 80 weeks in adults with type 2 diabetes. A1C fell by up to 1.6 points.
- TRIUMPH-3 (July 2026): 22.6% weight loss at 80 weeks in adults with severe obesity and heart disease.
TRIUMPH-3 also saw fewer heart events than placebo. But don’t read too much into that yet.
“The study was not designed to determine whether the drug reduces cardiovascular events.”
I broke down the full TRIUMPH-1 numbers, including the honest footnotes, in Retatrutide vs EloraTZP.
Action item: Remember the headline number as “28% at 80 weeks, without diabetes.” If you have type 2 diabetes, use “about 21%” instead.
Step 1: Lilly Files With the FDA in Early 2027
Lilly plans to file retatrutide for FDA approval in the first quarter of 2027. That’s the next real milestone. Nothing reaches pharmacies before it.
Lilly also plans later filings for knee osteoarthritis pain and sleep apnea linked to obesity. Those come after the main obesity filing.
Action item: Set a reminder for April 2027 to check whether Lilly announced the filing. That one press release tells you the clock has started.
Step 2: The FDA Review (Our Estimate)
After filing, the FDA takes time. A standard review of a brand-new drug usually takes about a year from submission. A priority review is shorter.
So our best guess is a decision somewhere between late 2027 and 2028. Analysts at Clarivate projected a 2028 launch, per PharmExec.
Could it be faster? Possibly. Lilly’s pill Foundayo was approved just 50 days after filing, thanks to a new FDA fast-track voucher program. If retatrutide gets the same treatment, mid-2027 is on the table. Nobody has said it will.
Action item: Plan around 2028. If it comes sooner, that’s a bonus, not a plan.
One drug may beat retatrutide to pharmacies: Novo’s CagriSema, which I compared in CagriSema vs EloraTZP.
Can You Get Retatrutide Today?
Two real routes exist, and both are narrow.
1. A clinical trial. Lilly is still running several retatrutide trials. You can search for open ones on ClinicalTrials.gov.
2. Early access. In August 2026, Lilly opened an expanded access program. It’s for adults with obesity that hasn’t responded to the highest approved dose of another drug, at least two serious obesity-related conditions, and no trial they can join. Doctors apply, not patients.
“Who meet specific medical criteria and cannot enroll in a clinical trial.”
Action item: If you think you might qualify for early access, ask your obesity specialist. They have to send the request.
What You’ll Probably Pay
Lilly hasn’t announced a price. Nobody knows yet.
The best clue is Lilly’s current pricing. Zepbound runs $299 to $449 a month cash with Lilly’s offer, and the Foundayo pill runs $149 to $299, per Ro. A stronger new drug is unlikely to launch cheaper than Zepbound. That’s our guess, not a leak.
Action item: Budget as if retatrutide costs at least what Zepbound does today. Then check your insurance once it’s approved.
A Worked Example: Waiting vs. Starting Now
Say you’re 240 pounds and deciding today. Here’s the rough math, using trial averages.
- Wait for retatrutide: maybe 18 months until it’s available, then 80 weeks to reach about 28%. That’s roughly 68 pounds, but the clock finishes around 2029 or later.
- Start Zepbound now: about 21% at 72 weeks. That’s roughly 50 pounds, finished by 2028.
Waiting could mean about 18 extra pounds, a year or more later. And you can likely switch later if retatrutide is approved and your doctor agrees. These are averages, not predictions for you.
If the price is what’s stopping you, I compared the cheaper pill route in Foundayo vs Zepbound.
Action item: Run this math with your own weight. Then ask your doctor whether starting now and switching later makes sense for you.
The Side Effect You Should Know About
Retatrutide is strong, and it’s not gentle. In TRIUMPH-1, 42.4% of people on 12 mg had nausea, versus 14.8% on placebo. About 11% quit the top dose because of side effects.
That’s a big reason a slower dose ramp may matter once it launches.
Action item: When retatrutide launches, ask about the slowest safe way to step up the dose.
What This Means for You
✅ You know the next milestone: an FDA filing in Q1 2027
✅ You know a realistic approval window: late 2027 to 2028
✅ You know the only real ways to get it today
✅ You won’t buy “retatrutide” from a random website
✅ You can weigh waiting against starting something now
The 5-Minute Version (Screenshot This)
- Status: retatrutide is not approved. Phase 3 trials succeeded in 2026.
- Next step: Lilly plans to file with the FDA in Q1 2027.
- Our estimate: a decision between late 2027 and 2028. Clarivate projects a 2028 launch.
- Today: only clinical trials or a narrow doctor-requested early-access program.
- Price: not announced. Expect at least Zepbound-level pricing.
Conclusion
When will retatrutide be available? Not this year, and probably not until late 2027 or 2028. The trials are done and the filing is coming. The FDA clock hasn’t started yet.
Your one action today: don’t buy retatrutide online, and if you’re ready for treatment now, ask your doctor about what’s approved today.
So tell me: are you waiting for retatrutide, or starting something now and switching later? Why?
MealCoach